We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
The most recent trading session ended with NRx Pharmaceuticals, Inc. (NRXP - Free Report) standing at $3.14, reflecting a +0.64% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily loss of 0.46%. On the other hand, the Dow registered a loss of 0.98%, and the technology-centric Nasdaq decreased by 0.64%.
Shares of the company have depreciated by 41.13% over the course of the past month, underperforming the Medical sector's loss of 4.9% and the S&P 500's loss of 3.04%.
Investors will be eagerly watching for the performance of NRx Pharmaceuticals, Inc. in its upcoming earnings disclosure.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for NRx Pharmaceuticals, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 73.91% downward. NRx Pharmaceuticals, Inc. is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 93, putting it in the top 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors
The most recent trading session ended with NRx Pharmaceuticals, Inc. (NRXP - Free Report) standing at $3.14, reflecting a +0.64% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily loss of 0.46%. On the other hand, the Dow registered a loss of 0.98%, and the technology-centric Nasdaq decreased by 0.64%.
Shares of the company have depreciated by 41.13% over the course of the past month, underperforming the Medical sector's loss of 4.9% and the S&P 500's loss of 3.04%.
Investors will be eagerly watching for the performance of NRx Pharmaceuticals, Inc. in its upcoming earnings disclosure.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for NRx Pharmaceuticals, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 73.91% downward. NRx Pharmaceuticals, Inc. is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 93, putting it in the top 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.